Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600Emutant microsatellite instabilityhigh (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC)
Nichole T
Here's what that distinction actually means in practice
LY3437943 demonstrated a safety and tolerability profile equivalent to other incretins in a phase 1 single ascending dosage study
10.1038/msb.2010.5 108 PengJ.LiQ.LiK.ZhuL.LinX.LinX.et al (2017)
US$ 25.26
US$ 24.31
US$ 25.05
US$ 20.47
US$ 24.67
US$ 24.67
US$ 23.59
US$ 21.89
US$ 20.17
